NCT00733265已完成1 期
Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Blood levels of AZD6140 in patients with severe kidney disease compared to volunteers with normal kidneys
研究概览
简要总结
The main purpose of this study is to examine how AZD6140 affects patients with severe kidney disease compared to volunteers with normal kidneys. Subjects in the study will receive one dose of AZD6140.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients must have severe kidney disease
- •Subjects who are matched to the kidney disease patients in terms of weight, age, and sex must have normal kidneys
- •All women must be post-menopausal (no longer menstruating) or surgically sterile
排除标准
- •Patients requiring dialysis
- •History of allergy to aspirin or clopidogrel
- •Have increased bleeding risk (for instance uncontrolled high blood pressure or a recent major injury)
- •Recent history of fainting or light-headedness
研究组 & 干预措施
AZD6140
Experimental
干预措施: AZD6140 (Drug)
结局指标
主要结局
Blood levels of AZD6140 in patients with severe kidney disease compared to volunteers with normal kidneys
时间窗: Scheduled times during the 3 days after the study drug is taken
次要结局
- Safety and tolerability of AZD6140 in patients with severe kidney disease compared to subjects with normal kidneys(Screening through completion of the study)
- Measure the effect of AZD6140 on how well blood clots in patients with severe kidney disease compared to subjects with normal kidneys(Scheduled times during the 3 days after the study drug is taken)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Assess the Pharmacokinetics of AZD6140 After Single Dose in Healthy Japanese Male VolunteersHealthyNCT01588626AstraZeneca12
已完成
1 期
Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT01082120AstraZeneca28
暂停
2 期
Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)Carcinoma, Renal CellKidney NeoplasmsNCT00065572AstraZeneca
撤回
1 期
A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of WarfarinPharmacokineticsPharmacodynamicsNCT01214122AstraZeneca
终止
1 期
AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal ImpairmentHeart Failure With Reduced Ejection Fraction (HFrEF)Renal ImpairmentNCT06611423AstraZeneca10